Treatment duration in the pivotal phase III trial1

ABRAXANE treatment duration for metastatic breast cancer
  • Patients treated with ABRAXANE received a median of 6 cycles of therapy
    • Range: 1-18 cycles
Dose modifications seen in the clinical trial

Treatment duration in the pivotal phase III trial1

ABRAXANE treatment duration for metastatic breast cancer
  • Patients treated with ABRAXANE received a median of 6 cycles of therapy
    • Range: 1-18 cycles
Dose modifications seen in the clinical trial

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.